Merck & rises 2.3% after presenting Phase 2b/3 trial data for remigromig

What happened

Merck & (MRK) rose 2.3% on October 9, 2026, after the company presented one-year data from the pivotal Phase 2b/3 BRUNELLO trial of remigromig (MK-3000), the results reported by Business Wire and GuruFocus. The session amounted to an ordinary sized move for the stock, and the presentation was the main development around the company that day. The stock’s market value was $359.61 billion.

How big was the move

The stock closed at $145.60, a rise of 2.3% on the day and a 0.9% increase over the last five sessions. Trading volume was 0.8 times its 20-day average. The S&P 500 rose 0.6% on the day while the Healthcare sector median rose 1.4%, leaving the stock 0.9 percentage points better than the sector median. The move measured 1.1 times a typical daily move for this stock and its beta of 0.27 indicates the stock tends to move less than the market.

Taken together, the price action looked like a routine market response rather than a sustained re-rating. The session did not depart from the stock’s recent pattern: the stock opened 0.7% below the previous close and settled into a modest gain by the close. Trading activity was lower than the recent average, suggesting limited conviction among buyers and sellers around the BRUNELLO update.

The technical picture

Technically the stock showed a mixed but generally favorable trend. The stock was 0.2% below its 20-day moving average and 1.5% above its 50-day moving average. It traded 17.5% above its 200-day moving average and had spent 233 consecutive trading days above that level, with the 50-day average above the 200-day average, a sign of an established uptrend. The Relative Strength Index (14 days) was 52, in a neutral range, and the shares were 7.2% below its 52-week high.

On performance, the stock rose 0.6% over one month, climbed 17.4% over three months and rose 68.5% over one year, putting it 52.9 percentage points ahead of the S&P 500 over the same period. Volatility was 33% annualized over 60 days, higher than 89% of its own readings over five years, indicating recent moves have been larger relative to the company’s recent history even as its market sensitivity remained low.

Fundamentals and valuation

For the four quarters through June 30, 2026, Merck & reported $66.40 billion in revenue, which grew 4.2% from a year earlier. Diluted earnings per share were $1.25, a decline of 80.7% from a year earlier, and operating margin was 16.7% compared with 33.6% a year earlier. Gross margin was 75.4% (a year earlier: 75.4%), free-cash-flow margin was 24.2%, and return on invested capital was 5.6%. The balance sheet showed net debt of 3.4 times EBITDA and share count over one year decreased by 1.6%.

Those results show a company with strong cash generation but pressured profitability. Revenue growth was modest while operating margin roughly halved year on year, a factor that helps explain the sharp fall in EPS. The balance sheet leverage of net debt of 3.4 times EBITDA is notable and is one of the items investors will weigh against the company’s cash-flow metrics.

On valuation metrics, the stock traded at 116.5 times trailing earnings and 53.2 times forward earnings, with a free-cash-flow yield of 4.5%. Its price-to-trailing-earnings reading is higher than 90% of its own readings over the past five years; the five-year median is 20.8 times earnings. PromtFinance scores placed Merck & at 59 for Value (Neutral), 34 for Growth (Weak), 94 for Quality (Exceptional), 85 for Momentum (Strong), 65 for Revisions (Positive) and 83 for Stability (Strong).

The juxtaposition of a very high price-to-earnings multiple and a strong Quality score suggests investors are pricing in durability of cash flow and product franchises despite near-term earnings pressure.

Earnings and analyst expectations

Merck & is slated to report next on October 29, 2026. The last report, on August 4, 2026, showed earnings per share of $-0.13 against $-0.27 expected, 51.9% above estimates. That marked six consecutive quarters beating estimates, with an average surprise of 18.9% above estimates over the last four reports. Historically, the typical two-day reaction after recent reports was that the stock fell 1.4%.

Analysts had a consensus price target of $159.59, which was 9.6% above the closing price, based on 38 analysts with ratings and with 68% assigning Buy or equivalent ratings; the consensus rating was Buy. Investors will watch the October 29 report for any guidance or commentary that could reconcile the company’s high valuation with its compressed operating margin and recent earnings volatility.

What to watch

• October 29, 2026: next scheduled earnings report.
• One-year BRUNELLO trial data for remigromig presented at AAO 2026, reported by Business Wire and GuruFocus.
• Valuation: 116.5 times trailing earnings and 53.2 times forward earnings.
• Balance-sheet leverage: net debt of 3.4 times EBITDA.
• Technical proximity: 7.2% below its 52-week high.